This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Acalabrutinib

AstraZeneca PLC

Drug Names(s): ACP196, ACP-196

Description: ACP-196 is a Bruton's tyrosine kinase (BTK) inhibitor.

Deal Structure: Merck and Acerta
At an undisclosed time, Merck granted Acerta rights to a wide array of kinase inhibitors. Details of the agreement were not disclosed.

AstraZeneca and Acerta
In December 2015, AstraZeneca announced that it has entered into an agreement to invest in a majority equity stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US.

Under the terms of the agreement, AstraZeneca will acquire 55% of the entire issued share capital of Acerta for an upfront payment of $2.5 billion. A further unconditional payment of $1.5 billion will be paid either on receipt of the first regulatory approval for acalabrutinib for any indication in the US, or the end of 2018, depending on which is first. The agreement also includes options which, if exercised, provide the opportunity for Acerta shareholders to sell, and AstraZeneca to buy, the remaining 45% of shares in Acerta. The options can be exercised at various...See full deal structure in Biomedtracker

Partners: Merck & Co., Inc. Acerta Pharma BV


Acalabrutinib News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug